C4 therapeutics presents pre-clinical data on cft8919, a selective degrader of egfr l858r, at keystone symposium on targeted protein degradation

– cft8919 induces tumor regression in pre-clinical models resistant to first- and third-generation egfr inhibitors –

CCCC Ratings Summary

CCCC Quant Ranking